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were associated with clinically significant PH (p = 0.014 
and p = 0.015, respectively). Continuous multi AT may 
be tolerated, but patients with high HAS-BLED score 
or VHD would require a careful attention during CIED 
implantations.
Keywords Cardiac surgery · Electrophysiology · 
Implanted cardiac defibrillators · Pacemakers
Abbreviations
ACE  Angiotensin converting enzyme
ANOVA  Analysis of variance
ARB  Angiotensin receptor blocker
AT  Antithrombotic therapy
BMI  Body mass index
CHF  Congestive heart failure
CI  Confidence interval
CIED  Cardiac implantable electronic device
CRT  Cardiac resynchronization therapy
CRT-D  Cardiac resynchronization therapy-defibrillator
CRT-P  Cardiac resynchronization therapy-pacemaker
DAPT  Dual antiplatelet therapy
DM  Diabetes mellitus
HT  Hypertension
ICD  Implantable cardioverter defibrillator
OAT  Oral anticoagulant therapy
NOAC  Novel oral anticoagulant
PH  Pocket hematoma
PM  Pacemaker
PT-INR  Prothrombin time-international ratio
SAPT  Single antiplatelet therapy
SD  Standard deviation
TAT  Triple antithrombotic therapy
TIA  Transient ischemic attack
VHD  Valvular heart disease
Abstract Previous studies showed that continuous anti-
coagulation or single antiplatelet therapy during implanta-
tions of cardiac implantable electronic devices (CIED) was 
relatively safe. However, the safety of continuous multi 
antithrombotic therapy (AT) in patients undergoing CIED 
interventions has not been clearly defined. We sought to 
evaluate the safety of this therapy during CIED implanta-
tions. A total of 300 consecutive patients (mean 69 years 
old, 171 males) with CIED implantations were enrolled 
in this study. The patients were divided into 6 groups [No-
AT, oral anticoagulant therapy (OAT), single antiplatelet 
therapy (SAPT), OAT and SAPT, dual antiplatelet therapy 
(DAPT), triple AT (TAT)], and the perioperative complica-
tions were evaluated. Clinically significant pocket hemato-
mas (PH) were defined as PH needing surgical intervention, 
prolonged hospitalizations, interruption of AT, or blood 
product transfusions. There were 129, 89, 49, 20, 10, and 3 
patients in No-AT, OAT, SAPT, OAT + SAPT, DAPT, and 
TAT groups, respectively. The occurrence of clinically sig-
nificant PH and thromboembolism did not differ among 6 
groups (p = 0.145 and p = 0.795, respectively). However, 
high HAS-BLED score and valvular heart disease (VHD) 
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Introduction
Current guidelines recommend that patients without a high 
thromboembolic risk should stop antithrombotic therapy 
(AT) because the implantation of cardiac implantable 
electronic devices (CIED) with the concomitant use of AT 
poses an increased risk of perioperative bleeding compli-
cations [1], but the interruption of antiplatelet and antico-
agulant drugs increases thromboembolic events [2–5]. On 
the other hand, previous studies showed that continuous 
anticoagulation during CIED implantations was safe, and 
a previous report revealed that antiplatelet therapy should 
not be stopped before low-invasive surgeries because local 
hematomas are easy to control their bleeding [6–9]. Thus, 
continuous AT during CIED implantations has been rec-
ommended recently. In previous reports, a considerable 
number of patients with multi (dual or triple) AT were 
included. However, the safety of continuous multi AT in 
patients undergoing CIED implantations has not been suf-
ficiently evaluated [10–13]. In this study, we sought to 




This study was a retrospective observational study. The 
study population consisted of consecutive patients who 
underwent CIED [pacemaker (PM), implantable car-
dioverter defibrillator (ICD), cardiac resynchronization 
therapy (CRT)-pacemaker (CRT-P), or CRT-defibrillator 
(CRT-D)] implantations without heparin bridging therapy 
in 2012. All patients who underwent the device surgery 
continued AT through the procedure. All patients under-
went procedures with the standard techniques for a pec-
toral subfascial pocket formation and transvenous lead 
placement by way of the subclavian vein using tined or 
screw-in leads. All right atrial and right ventricular leads 
were positioned in the right auricular appendage and right 
ventricular apex, respectively. The left ventricular leads 
were positioned in the lateral, posterolateral, or anterior 
cardiac vein. Written informed consent was obtained from 
each patient in this study to undergo a CIED implantation. 
The privacy of the patients was protected by the anonymi-
zation of all data.
Study protocol
Three hundred patients were enrolled in this study. Patients 
were divided into 6 groups as follows; No-AT group: 
patients without any AT, OAT group: patients with oral 
anticoagulant therapy (OAT), SAPT group: patients with 
single antiplatelet therapy (SAPT), OAT + SAPT group: 
patients with OAT and SAPT, DAPT group: patients with 
dual antiplatelet therapy (DAPT), and TAT group: patients 
with triple antithrombotic therapy (TAT). They were eval-
uated for any perioperative complications (bleeding or 
thromboembolic events) occurring within 30 days of the 
surgery. Bleeding events included pocket hematomas (PH), 
clinically significant PH, cerebral bleeding, gastrointestinal 
bleeding, and cardiac tamponade. The definition of PH was 
bleeding not requiring additional intervention but requiring 
treatment with compress. Clinically significant PH were 
defined as bleeding requiring surgical intervention, pro-
longation of hospitalization, interruption of AT, and blood 
product transfusions. Thromboembolic events included 
strokes, transient ischemic attacks (TIAs), myocardial 
infarctions, pulmonary embolisms, and deep vein thrombo-
sis. Furthermore, the predictors of clinically significant PH 
were evaluated.
Patient data collection and perioperative risk 
evaluation
The patient characteristics, including the co-morbidities 
and medication history, and procedural details were col-
lected at the time of the CIED implantation. The HAS-
BLED [hypertension, abnormal renal/liver function, 
stroke, bleeding history or predisposition, labile inter-
national normalized ratio, elderly (>65 years), drugs/
alcohol] score was used to assess the bleeding risk, and 
scored hypertension (HT), abnormal renal/liver function 
(1 point each), strokes, bleeding history or a predispo-
sition to it, labile international normalized ratio, being 
elderly (>65 years), and drugs/alcohol use (1 point each) 
[14]. If the HAS-BLED score was ≥3, a patient was con-
sidered to have a considerable risk of bleeding [15–17]. 
Every thromboembolic risk factor was evaluated and we 
assessed the thromboembolic risk using the CHADS2 
and CHA2DS2-VASc scores [14, 17–19]. The CHADS2 
score assigned 1 point each for congestive heart failure 
(CHF), HT, age ≥75 years, and diabetes mellitus (DM), 
and 2 points for a history of a stroke or TIA [14]. The 
CHA2DS2-VASc score assigned 1 point each for CHF, 
HT, age 65–74 years, DM, vascular disease, a female 
sex; and 2 points for an age ≥75 years, and a history of a 
stroke or TIA [18]. If the CHA2DS2-VASc score was ≥2, 
a patient was considered to have a considerable risk of a 
thromboembolism [19].
Statistical analysis
The statistical analyses were performed using JMP version 
9 software (SAS Institute Inc., Tokyo, Japan). The results 
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are expressed as the mean ± SD for continuous variables. 
Categorical data are presented as numbers (%). Differ-
ences among groups were analyzed by using the t-test 
for unpaired data, Chi-square test, and Fisher exact test, 
as appropriate. Differences in continuous variables were 
assessed using a one-way analysis of variance (ANOVA). A 
p value <0.05 was considered significant. Logistic regres-
sion analysis was used to estimate the magnitude of associ-
ation [i.e., odds ratios (ORs)] between clinically significant 
PH and clinical characteristics.
Results
Clinical characteristics of No‑AT, OAT, SAPT, 
OAT + SAPT, DAPT and TAT groups
The baseline characteristics are listed in Table 1. The 
number of patients in No-AT, OAT, SAPT, OAT + SAPT, 
DAPT, and TAT groups was 129, 89, 49, 20, 10 and 3, 
respectively. The mean patient age was 69 years; 171 
(57 %) were male. The frequency of ischemic heart disease, 
Table 1  Comparison of the clinical characteristics among No-AT, OAT, SAPT, OAT + SAPT, DAPT, and TAT groups
Values are given as the n (%) or mean ± standard deviation
ACE angiotensin converting enzyme, ARB angiotensin receptor blocker, AT antithrombotic therapy, BMI body mass index, DAPT dual antiplate-
let therapy, NOAC novel oral anticoagulant, OAT oral anticoagulant therapy, PT-INR prothrombin time-international ratio, SAPT single antiplate-
















Age (years) 69 ± 16 66 ± 19 69 ± 14 75 ± 11 72 ± 10 65 ± 12 64 ± 21 0.017
Male 171 (57) 68 (53) 41 (46) 34 (69) 15 (75) 10 (100) 3 (100) <0.001
Body height (cm) 159 ± 11 159 ± 11 158 ± 10 159 ± 8 162 ± 10 167 ± 10 166 ± 3 0.155
Body weight (kg) 55 ± 11 55 ± 11 53 ± 12 56 ± 10 56 ± 11 62 ± 9 62 ± 6 0.101
BMI 22 ± 3 22 ± 3 21 ± 4 22 ± 3 21 ± 4 22 ± 2 23 ± 3 0.349
Serum creatinine 
(mg/dl)
1.1 ± 0.7 0.9 ± 0.4 1.2 ± 0.8 1.4 ± 1.1 1.3 ± 0.6 1.0 ± 0.2 1.1 ± 0.3 <0.001
Blood hemoglobin 
(g/dl)
12.7 ± 1.8 13.0 ± 1.6 12.6 ± 1.8 12.6 ± 1.8 12.5 ± 2.2 12.2 ± 2.4 12.4 ± 1.4 0.439
Diabetes mellitus 68 (23) 16 (12) 19 (21) 18 (37) 9 (45) 5 (50) 1 (33) <0.001
Hypertension 147 (49) 61 (47) 32 (36) 35 (71) 11 (55) 6 (60) 2 (67) 0.004
Ischemic heart 
disease
54 (18) 3 (2) 2 (2) 26 (53) 11 (55) 9 (90) 3 (100) <0.001
Valvular heart 
disease
23 (8) 2 (2) 18 (20) 1 (2) 2 (10) 0 (0) 0 (0) <0.001
Atrial fibrillation 82 (27) 11 (9) 52 (58) 2 (4) 15 (75) 0 (0) 2 (67) <0.001
Drug
 Anticoagulant drug
  Warfarin 107 (36) – 85 (96) – 19 (95) – 3 (100) –
  Control of  
PT-INR
1.7 ± 0.4 – 1.7 ± 0.4 – 1.8 ± 0.5 – 1.4 ± 0.3 –
  NOAC 5 (1) – 4 (4) – 1 (5) – 0 (0) –
 Antiplatelet drug
  Aspirin 74 (25) – – 41 (84) 20 (100) 10 (100) 3 (100) –
  Thienopyridine 13 (4) – – 2 (4) 0 (0) 8 (80) 3 (100) –
  Cilostazol 8 (3) – – 6 (12) 0 (0) 2 (20) 0 (0) –
β-Blocker 138 (46) 39 (30) 55 (62) 23 (47) 13 (65) 6 (60) 2 (67) <0.001
ACE inhibitor/
ARB
143 (48) 45 (35) 52 (58) 27 (55) 9 (45) 7 (70) 3 (100) 0.002
Statin 101 (34) 27 (21) 25 (28) 29 (59) 10 (50) 7 (70) 3 (100) <0.001
Diuretics 141 (47) 32 (25) 65 (73) 24 (49) 11 (55) 6 (60) 3 (100) <0.001
Amiodarone 51 (17) 10 (8) 22 (25) 10 (20) 4 (20) 3 (30) 2 (67) 0.002
336 Heart Vessels (2017) 32:333–340
1 3
valvular heart disease (VHD), and atrial fibrillation was 18, 
8 and 27 %, respectively. The rate of anticoagulant drug use 
was 37 %, and a novel oral anticoagulant (NOAC) use was 
observed in only 5 patients in this study. The prothrom-
bin time-international ratio (PT-INR) as a warfarin control 
parameter was 1.7 and there was no significant difference 
in the PT-INR among OAT, OAT + SAPT, and TAT groups. 
The rate of antiplatelet drug use was 32 %.
Procedural data of No‑AT, OAT, SAPT, OAT + SAPT, 
DAPT and TAT groups
The frequency of a large device (ICD and CRT-D), de novo 
implantation, and system upgrade were 44, 63 and 3 %, 
respectively. The mean procedure time was 1.8 h. There 
were no significant differences among the 6 groups regard-
ing the CRD type, rate of de novo implantations, system 
upgrades, or procedure time (Table 2).
Bleeding and thromboembolic risk data of No‑AT, OAT, 
SAPT, OAT + SAPT, DAPT, and TAT groups
The bleeding and thromboembolic risk data of the 6 groups 
is shown in Table 3. The mean HAS-BLED score, CHADS2 
score, and CHA2DS2-VASc score was 1.2, 1.8, and 3.2, 
respectively. HAS-BLED score ≥3 as a high bleeding risk 
parameter was 21 (7 %) and significant difference among 
the 6 groups. CHA2DS2-VASc score ≥2 as a considerable 
thromboembolic risk parameter was 247 (82 %) and signif-
icant difference among the 6 groups.
Perioperative complication data of No‑AT, OAT, SAPT, 
OAT + SAPT, DAPT, and TAT groups
PH and clinically significant PH occurred 17 (6 %) and 9 
(3 %) patients, respectively. The frequency of PH was signif-
icantly different, but the frequency of clinically significant 
PH was not different among the 6 groups (Fig. 1). The gas-
trointestinal bleeding occurred 2 (1 %) and there was no 
significant difference among the 6 groups (p = 0.113). No 
subjects had any cardiac tamponade and cerebral bleeding.
Thromboembolic event occurred in only one patient and 
there was no significant difference in the frequency of that 
event among the 6 groups (p = 0.795).
Predictors of clinically significant PH
The frequency of VHD [OR 6.8; 95 % confidence interval 
(CI) 1.4–27.8; p = 0.010] or high HAS-BLED score (OR 
2.2; 95 % CI 1.1–4.3; p = 0.021) were major predictors of 
clinically significant PH by univariate analysis, as shown in 
Table 4. In addition, low body mass index (OR 0.78; 95 % CI 
0.6–0.98; p = 0.040) was also a significant predictor of clini-
cally significant PH by univariate analysis. The frequency of 
VHD (OR 7.2; 95 % CI 1.3–35.0; p = 0.015) or high HAS-
BLED score (OR 2.5; 95 % CI 1.2–5.3; p = 0.014) remained 
significant independent predictors of clinically significant 
PH developing by multivariate analysis.
Discussion
To the best of our knowledge, this is the first report on the 
comprehensive data concerning the safety of continuous 
multi AT during CIED implantations. The results of this 
study revealed that continuous multi AT was acceptable 
but high HAS-BLED and VHD were independent predic-
tors of clinically significant PH during CIED implantations. 
These findings suggested that continuous multi AT may be 
tolerated, but patients with high HAS-BLED score or VHD 
would require a careful attention during CIED implantations.
Although the rate of clinically significant PH did not dif-
fer significantly among the 6 groups in our study, 5 % of 
that complication rate in AT was relatively high. Previous 
Table 2  Comparison of the procedural data among No-AT, OAT, SAPT, OAT + SAPT, DAPT, and TAT groups
Values are given as the n (%) or mean ± standard deviation
AT antithrombotic therapy, CIED cardiac implantable electronic device, CRT-D cardiac resynchronization therapy-defibrillator, CRT-P cardiac 
resynchronization therapy-pacemaker, DAPT dual antiplatelet therapy, ICD implantable cardioverter-defibrillator, OAT oral anticoagulant ther-
















Type of CIED 0.522
 PM and CRT-P 167 (56) 75 (58) 52 (58) 27 (55) 8 (40) 4 (40) 1 (33)
 ICD and CRT-D 133 (44) 54 (42) 37 (42) 22 (45) 12 (60) 6 (60) 2 (67)
De novo implanta-
tion
190 (63) 78 (60) 54 (61) 35 (71) 13 (65) 7 (70) 3 (100) 0.540
System upgrade 10 (3) 4 (3) 3 (3) 3 (6) 0 (0) 0 (0) 0 (0) 0.800
Procedure time (h) 1.8 ± 0.9 1.8 ± 0.7 1.9 ± 1.1 2.1 ± 1.2 1.9 ± 0.7 1.7 ± 0.7 2.3 ± 0.9 0.482
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studies revealed that a perioperative continuous single AT 
was associated with an incidence of PH of 1.9–6.6 % [20–
27]. Thus, the clinically significant PH rate of the multi AT 
in our study may be acceptable.
The incidence of thromboembolic events was rare and 
did not differ significantly among the 6 groups in this study. 
The thromboembolic event rate of the single AT was 0–1 % 
in previous studies [20–23]. Continuous multi AT may be 
effective in suppressing thromboembolic events within the 
perioperative period.
High HAS-BLED score and VHD were independ-
ent predictors of clinically significant PH during CIED 
implantations in this study. There is no report revealing 
that VHD is associated with bleeding complication dur-
ing CIED implantations; however, one previous study 
said that the observed risk of bleeding was higher with 
AT in patients with VHD compared with patients with-
out VHD [28]. Since VHD is a considerable disease, spe-
cific attention is needed in this population during CIED 
implantations.
Table 3  Comparison of the bleeding and thromboembolic risk data among No-AT, OAT, SAPT, OAT + SAPT, DAPT, and TAT groups
Values are given as the n (%) or mean ± standard deviation


















 HAS-BLED score 1.2 ± 0.9 0.8 ± 0.7 1.0 ± 0.7 2.0 ± 0.8 2.1 ± 0.6 2.0 ± 1.0 1.7 ± 0.6 <0.001
 HAS-BLED score ≥3 21 (7) 2 (2) 3 (3) 10 (20) 2 (10) 4 (40) 0 (0) 0.001
Thromboembolic risk data
 Prior stroke/recurrent  
venous thromboembolism
34 (11) 4 (3) 14 (16) 8 (16) 7 (35) 0 (0) 1 (33) <0.001
 Active cancer 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) –
 Thrombophilia 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) –
 CHADS2 score 1.8 ± 1.3 1.2 ± 1.2 1.9 ± 1.1 2.5 ± 1.3 2.8 ± 1.3 1.8 ± 0.8 2.7 ± 2.1 <0.001
 CHA2DS2-VASc score 3.2 ± 1.8 2.5 ± 1.6 3.3 ± 1.5 4.3 ± 1.7 4.7 ± 1.6 3.4 ± 1.0 4.3 ± 2.5 <0.001
 CHA2DS2-VASc score ≥2 247 (82) 88 (68) 80 (90) 47 (96) 19 (95) 10 (100) 3 (100) <0.001
Fig. 1  a Pocket hematoma and clinically significant pocket hema-
toma among No-AT, OAT, SAPT, OAT + SAPT, DAPT, and TAT 
groups. The frequency of PH was 3, 7, 4, 25, 0 and 0 % in No-AT, 
OAT, SAPT, OAT + SAPT, DAPT and TAT groups, respectively, and 
was significantly different among the 6 groups. b The frequency of 
clinically significant PH was 1, 6, 2, 10, 0 and 0 % in No-AT, OAT, 
SAPT, OAT + SAPT, DAPT and TAT groups, respectively, and was 
not different among the 6 groups. AT antithrombotic therapy, DAPT 
dual antiplatelet therapy, OAT oral anticoagulant therapy, PH pocket 
hematoma, SAPT single antiplatelet therapy, TAT triple antithrom-
botic therapy
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There were many warfarin users in our study, so our 
results are acceptable for patients with warfarin. The mean 
PT-INR of the warfarin users in this study was 1.7 and 
it was a low control level considering the previous data 
[29, 30]. The bleeding risk in Asians is greater than that 
of the people in the other countries [31]. Previous Japa-
nese registries revealed that a PT-INR of 1.6–2.6 was safe 
and effective in preventing thromboembolic events, par-
ticularly in patients aged ≥70 years old [32–34]. The rec-
ommended PT-INR in the Japanese guidelines is 2.0–3.0 
and 1.6–2.6 for patients aged <70 years and ≥70 years, 
respectively [33]. Thus, our control level of the PT-INR 
was acceptable. In contrast, only 1 % of the patients used 
NOACs, so we could not sufficiently evaluate the safety 
and efficacy of NOACs. Previous studies revealed that 
continuous NOAC use was safe during CIED implanta-
tions [10, 11]. Thus, multi AT including NOACs may be 
safe and effective.
Limitations
There are several limitations to our study. The patient 
number in this study, especially for NOAC users, was 
very small. The evaluation of large number in this topic 
is needed by a future study. Furthermore, procedures per-
formed by experienced operators carry a lower risk of clini-
cally significant PH compared with trainees and less experi-
enced operators [25, 26, 35]. Our hospital is a high-volume 
center (mean operation procedures, 500 per year) for CIED 
implantations, and experienced operators performed all sur-
geries in our study. A future multi-center study is needed to 
resolve this problem.
Conclusions
Continuous multi AT may be tolerated, but patients with 
high HAS-BLED score or VHD would require a careful 
attention during CIED implantations.
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